In our urinary proteomics analysis, PRDX1 was found to be significantly upregulated in the urine of BLCA patients compared to healthy controls, suggesting its potential utility as a non-invasive diagnostic biomarker. Here, PRDX1 is linked to bladder transitional cell carcinoma.